Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Zealand Pharma A/S
  6. News
  7. Summary
    ZEAL   DK0060257814

ZEALAND PHARMA A/S

(ZEAL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

European ADRs Move Higher in Wednesday Trading

10/13/2021 | 11:10am EST


ę MT Newswires 2021
All news about ZEALAND PHARMA A/S
11/30ZEALAND PHARMA MAJOR SHAREHOLDER ANN : The Capital Group Companies, 2021
AQ
11/29ZEALAND PHARMA MAJOR SHAREHOLDER ANN : Credit Suisse Group AG, 2021
AQ
11/22ZEALAND PHARMA A/S : announces successful outcome of Phase 1b clinical trial with GLP1-GLP..
PU
11/22Zealand Pharma Says Dapiglutide Safe, Well-Tolerated in Phase 1b Trial
MT
11/22Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 d..
GL
11/22Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 D..
CI
11/19ZEALAND PHARMA A/S : Company announcement – No. 69/ 2021 Company announcement &ndash..
PU
11/19Zealand Pharma increases its share capital as a consequence of exercise of employee war..
AQ
11/17European ADRs Higher Wednesday as Credit Suisse, Barrick Gold Gain
MT
11/12European ADRs Move Lower in Friday Trading
MT
More news
Analyst Recommendations on ZEALAND PHARMA A/S
More recommendations
Financials
Sales 2021 293 M 44,6 M 44,6 M
Net income 2021 -1 005 M -153 M -153 M
Net cash 2021 770 M 117 M 117 M
P/E ratio 2021 -5,37x
Yield 2021 -
Capitalization 5 807 M 882 M 884 M
EV / Sales 2021 17,2x
EV / Sales 2022 12,0x
Nbr of Employees 346
Free-Float 99,0%
Chart ZEALAND PHARMA A/S
Duration : Period :
Zealand Pharma A/S Technical Analysis Chart | ZEAL | DK0060257814 | MarketScreener
Technical analysis trends ZEALAND PHARMA A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 134,40 DKK
Average target price 239,80 DKK
Spread / Average Target 78,4%
EPS Revisions
Managers and Directors
Emmanuel Dulac President & Chief Executive Officer
Matthew D. Dallas Chief Financial Officer & Senior Vice President
Alf Gunnar Martin Nicklasson Chairman
Adam Sinding Steensberg Chief Medical Officer, EVP-Research & Development
Danilo Verge Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
ZEALAND PHARMA A/S-39.08%882
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819